ARTICLE | Product Development
A new chapter for progressive MS?
NIH’s Reich on recent data that could shape drug development’s future for progressive multiple sclerosis, and neurodegeneration broadly
October 15, 2024 10:07 PM UTC
While the multiple sclerosis field has delivered increasingly efficacious drugs for patients with relapsing disease, strategies for treating patients who’ve advanced to progressive disease have remained elusive.
According to Daniel Reich, senior investigator at NIH and director of the Translational Neuroradiology Section of the National Institute of Neurological Disorders and Stroke (NINDS), recent data from Sanofi (Euronext:SAN; NASDAQ:SNY) open the door to solving the problem. The topline results in relapsing-remitting disease were not what the pharma was looking for, but there are important signals in the data, Reich told BioCentury. ...